CTDH News and Press, Ctd Holdings Inc From 05/20/20

Thinly traded nano cap Cyclo Therapeutics ( OTCQB:CTDH -6.6% ) announces topline results from 25 participants in two clinical trials, a Phase 1 and a Phase 1/2 , assessing the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of two and three dose regimen...

Top line results of Phase I study confirm favorable safety and tolerability of Trappsol ® Cyclo™ in patients with NPC1 and demonstrate biological responses for both dose groups. An Unblinded Interim Analysis of Phase I/II study shows encouraging signals in efficacy for all do...

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that it will hold a call for investors and the NPC community on Wedne...

Company reported in March 2020 that FDA had also provided positive feedback on the pivotal trial design Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C1 (NPC1) and Al...

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that the international patent application titled “Methods for ...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that it has closed a private placement of its securities with a group...

Thinly traded nano cap Cyclo Therapeutics ( OTCQB:CTDH   +7% ) is up, albeit on modest turnover of 43K shares, in reaction to positive safety data from a Phase 1 clinical trial evaluating lead candidate Trappsol Cyclo in patients with Niemann-Pick Disease Type C1 , a rare (1 in 100K ...

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that the Safety Review Committee for its Phase I trial in NPC has det...

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease, today announced that it has completed patient enrollment in its Extension Protocol to the P...